I am pleased to confirm the first UK approval for the treatment of Friedreich’s ataxia, omaveloxolone. “We’re assured that the appropriate regulatory standards of safety, quality ...

Treatment goals for Friedreich ataxia include symptom management, slowing disease progression, and enhancing quality of life through multidisciplinary care. Supportive therapies address ...

There is currently no cure for Friedreich’s ataxia. Treatment focuses on managing your symptoms and improving your quality of life to help you maintain your daily function and activities as long ...

Biogen Canada Inc. is disappointed by INESSS's recommendation against listing SKYCLARYS™ (omaveloxolone), despite its therapeutic potential for individuals living with Friedreich ataxia (FA) — a ...

Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; ...

Video content above is prompted by the following: Could you elaborate on the differential diagnosis for this disease, how it is definitively diagnosed and the impact of receiving such a diagnosis ...

TORONTO, March 17, 2025 /CNW/ - Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 ...

Matt is a paid spokesperson for Biogen. SKYCLARYS is used for the treatment of Friedreich ataxia in adults and adolescents aged 16 years and older. Please see full Prescribing Information and ...